Miriam Escarlet Díaz-Galicia

Ms. Miriam Escarlet Díaz-Galicia

King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center (CBRC), Biological and Environmental Science and Engineering (BESE), Thuwal, 23955-6900, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
KGKeying Guo
Keying Guo
SWShofarul Wustoni
Shofarul Wustoni
AKAnil Koklu
Anil Koklu
MDMiriam Escarlet Díaz-Galicia
Miriam Escarlet Díaz-Galicia
MMMaximilian Moser
Maximilian Moser
SISahika Inal
Sahika Inal

11 June 2018 in Cancers
Verified
Journal Article
Open access
PDF file
RNRayan Naser
Rayan Naser
AAAbdullah Aldehaiman
Abdullah Aldehaiman
MDMiriam Escarlet Díaz-Galicia
Miriam Escarlet Díaz-Galicia
SAStefan Arold
Stefan Arold
Focal adhesion kinase (FAK) and its close paralogue, proline-rich tyrosine kinase 2 (PYK2), are key regulators of aggressive spreading and metastasis of cancer cells. While targeted small-molecule inhibitors of FAK and PYK2 have been found to have promising antitumor activity, their clinical long-term efficacy may be undermined by the strong capacity of cancer cells to evade anti-kinase drugs. In healthy cells, the expression and/or function of FAK and PYK2 is tightly controlled via modulation of gene expression, competing alternatively spliced forms, non-coding RNAs, and proteins that directly or indirectly affect kinase activation or protein stability. The molecular factors involved in this control are frequently deregulated in cancer cells. Here, we review the endogenous mechanisms controlling FAK and PYK2, and with particular focus on how these mechanisms could inspire or improve anticancer therapies.

31 December 2023 in Advanced Science
Verified
Journal Article
Open access
KGKeying Guo
Keying Guo
RGRaik Grünberg
Raik Grünberg
YRYuxiang Ren
Yuxiang Ren
TCTianrui Chang
Tianrui Chang
SWShofarul Wustoni
Shofarul Wustoni
SISahika Inal
Sahika Inal
Electronic immunosensors are indispensable tools for diagnostics, particularly in scenarios demanding immediate results. Conventionally, these sensors rely on the chemical immobilization of antibodies onto electrodes. However, globular proteins tend to adsorb and unfold on these surfaces. Therefore, self‐assembled monolayers (SAMs) of thiolated alkyl molecules are commonly used for indirect gold–antibody coupling. Here, a limitation associated with SAMs is revealed, wherein they curtail the longevity of protein sensors, particularly when integrated into the state‐of‐the‐art transducer of organic bioelectronics—the organic electrochemical transistor. The SpyDirect method is introduced, generating an ultrahigh‐density array of oriented nanobody receptors stably linked to the gold electrode without any SAMs. It is accomplished by directly coupling cysteine‐terminated and orientation‐optimized spyTag peptides, onto which nanobody‐spyCatcher fusion proteins are autocatalytically attached, yielding a dense and uniform biorecognition layer. The structure‐guided design optimizes the conformation and packing of flexibly tethered nanobodies. This biolayer enhances shelf‐life and reduces background noise in various complex media. SpyDirect functionalization is faster and easier than SAM‐based methods and does not necessitate organic solvents, rendering the sensors eco‐friendly, accessible, and amenable to scalability. SpyDirect represents a broadly applicable biofunctionalization method for enhancing the cost‐effectiveness, sustainability, and longevity of electronic biosensors, all without compromising sensitivity.

8 May 2018 in Preprints.org
Verified
Preprint
Open access
RNRayan Naser
Rayan Naser
AAAbdullah Aldehaiman
Abdullah Aldehaiman
MDMiriam Escarlet Díaz-Galicia
Miriam Escarlet Díaz-Galicia
SAStefan T. Arold
Stefan T. Arold
Focal adhesion kinase (FAK) and its close paralogue, proline-rich tyrosine kinase 2 (PYK2), are key regulators of aggressive spreading and metastasis of cancer cells. While targeted small-molecule inhibitors of FAK and PYK2 are showing promising antitumor activity, their clinical long-term efficacy may be undermined by the strong capacity of cancer cells to evade anti-kinase drugs. In healthy cells, the expression and/or function of FAK and PYK2 is tightly controlled through modulation of gene expression, competing alternatively spliced forms, non-coding RNAs, and proteins that directly or indirectly affect kinase activation or protein stability. The molecular factors involved are frequently deregulated in cancer cells. Here, we review the endogenous mechanisms controlling FAK and PYK2, and discuss how these mechanisms could inspire or improve anticancer therapies.

19 January 2022 in Biosensors
Verified
Journal Article
Open access
PDF file
MDMiriam Escarlet Díaz-Galicia
Miriam Escarlet Díaz-Galicia
RGRaik Grünberg
Raik Grünberg
SAStefan Arold
Stefan Arold
CRISPR-Cas systems have a great and still largely untapped potential for in vitro applications, in particular, for RNA biosensing. However, there is currently no systematic guide on selecting the most appropriate RNA-targeting CRISPR-Cas system for a given application among thousands of potential candidates. We provide an overview of the currently described Cas effector systems and review existing Cas-based RNA detection methods. We then propose a set of systematic selection criteria for selecting CRISPR-Cas candidates for new applications. Using this approach, we identify four candidates for in vitro RNA.

13 November 2020 in medRxiv
Verified
Preprint
Open access
PDF file
KGKeying Guo
Keying Guo
SWShofarul Wustoni
Shofarul Wustoni
AKAnil Koklu
Anil Koklu
MDMiriam Escarlet Díaz-Galicia
Miriam Escarlet Díaz-Galicia
MMMaximilian Moser
Maximilian Moser
SISahika Inal
Sahika Inal
The COVID-19 pandemic highlights the need for rapid protein detection and quantification at the single-molecule level in a format that is simple and robust enough for widespread point-of-care applications. We here introduce a modular nanobody-organic electrochemical transistor architecture that enables the fast and specific detection and quantification of single-molecule to nanomolar protein antigen concentrations in complex bodily fluids. The sensor combines a new solution-processable organic semiconductor material in the transistor channel with the high-density and orientation-controlled bioconjugation of nanobody fusion proteins on disposable gate electrodes. It provides results after a 10 minutes exposure to 5 µL of unprocessed samples, maintains high specificity and single-molecule sensitivity in human saliva or serum, and is rapidly reprogrammed towards any protein target for which nanobodies exist. We demonstrate the use of this highly modular platform for the detection of green fluorescent protein, SARS-CoV-1/2, and MERS-CoV spike proteins and validate the sensor for COVID-19 screening in unprocessed clinical nasopharyngeal swab and saliva samples.